“European Liver Patient Association has made significant contributions from patent, scientific, policy, regulatory, and corporate perspectives. Its patient-centric approach, scientific collaborations, policy advocacy, regulatory engagement, and corporate partnerships have collectively improved the lives of liver patients and advanced liver health across Europe.”

“ELPA’s corporate partnerships have enabled the organization to expand its reach and impact, leveraging resources and expertise to implement impactful initiatives. The association’s collaboration with corporate entities has helped raise awareness, enhance patient support programs, and advocate for improved access to treatments and healthcare services.”

“ELPA’s collaborations with pharmaceutical companies and industry stakeholders have fostered partnerships that drive innovation in liver disease research and treatment. The association’s industry engagement has facilitated knowledge transfer, funding opportunities, and the development of patient-centric solutions.”

“Encourage corporate sponsors to invest in liver disease awareness campaigns, patient education programs, and community outreach activities, fostering a supportive ecosystem for liver patients.”

“ELPA’s collaborative approach with policymakers and government agencies has ensured that the voices of liver patients are heard and their concerns are addressed. The organization’s efforts in shaping policies that promote early detection, prevention, and equitable access to treatments have had a positive impact on liver health across Europe.”

“ELPA has been actively engaged in advocating for policies that prioritize liver health at the national and European levels. The association’s policy recommendations have highlighted the need for increased funding, improved access to healthcare services, and better prevention strategies.”